PROSCA/BLADDR 2022 | IsoPSA: blood-based assay for improved detection of prostate cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses IsoPSA, a blood-based test that assesses prostate cancer risk by detecting cancer-specific structural isoforms of prostate specific antigen (PSA). IsoPSA is more accurate than PSA at predicting likelihood of prostate cancer, and in a prospective study, reduced incidence of unnecessary biopsies by 50%. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.